Abstract
Background: Thyroid hormone (T3) is essential for normal development of children enabling brain development and somatic growth. However, certain individuals are genetically predisposed with insufficient or no thyroid hormones. Such a condition is termed congenital hypothyroidism (CH).
Objective: In the present review, a brief back ground about congenital hypothyroidism, factors associated with CH leading to thyroid dysgenesis and thyroid dyshormonogenesis is elaborated. Additionally, the guidelines for available treatment options, management and follow-up required for patients diagnosed with CH are discussed. Treatment options in terms of treatment initiation and dosage of hormone replacement are discussed. Conclusion: Though CH is considered as the most common neonatal metabolic disorder, it is also easily treatable compared to other metabolic or hereditary diseases. The outcome of CH treatment depends on the compliance of parents early in life and by patients themselves during later part of life.Keywords: Congenital hypothyroidism, hormone therapy, levothyroxine, thyroid gland, transcription factors, Thyroid hormone (T3).
Current Pharmaceutical Design
Title:Congenital Hypothyroidism: Facts, Facets & Therapy
Volume: 23 Issue: 16
Author(s): Yedukondalu Kollati, Ranga Rao Ambati, Prakash Narayana Reddy, N. Satya Sampath Kumar, Rajesh K. Patel*Vijaya R. Dirisala*
Affiliation:
- Sandor Animal Biogenics Private Limited, Sandor Life Sciences, Telangana-500043,India
- Department of Biotechnology, Vignan’s Foundation for Science, Technology and Research University (VFSTRU), Guntur-5222, Andhra Pradesh,India
Keywords: Congenital hypothyroidism, hormone therapy, levothyroxine, thyroid gland, transcription factors, Thyroid hormone (T3).
Abstract: Background: Thyroid hormone (T3) is essential for normal development of children enabling brain development and somatic growth. However, certain individuals are genetically predisposed with insufficient or no thyroid hormones. Such a condition is termed congenital hypothyroidism (CH).
Objective: In the present review, a brief back ground about congenital hypothyroidism, factors associated with CH leading to thyroid dysgenesis and thyroid dyshormonogenesis is elaborated. Additionally, the guidelines for available treatment options, management and follow-up required for patients diagnosed with CH are discussed. Treatment options in terms of treatment initiation and dosage of hormone replacement are discussed. Conclusion: Though CH is considered as the most common neonatal metabolic disorder, it is also easily treatable compared to other metabolic or hereditary diseases. The outcome of CH treatment depends on the compliance of parents early in life and by patients themselves during later part of life.Export Options
About this article
Cite this article as:
Kollati Yedukondalu, Ambati Rao Ranga, Reddy Narayana Prakash, Kumar Satya Sampath N., Patel K. Rajesh*, Dirisala R. Vijaya*, Congenital Hypothyroidism: Facts, Facets & Therapy, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170206124255
DOI https://dx.doi.org/10.2174/1381612823666170206124255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Prediction Models and Scores in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Life-history Constraints on the Mechanisms that Control the Rate of ROS Production
Current Genomics Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Usefulness of Magnetic Resonance Imaging in Cardiac and Enovascular Intervention
Current Medical Imaging Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design